Biocon Biologics Reports Promising Phase 3 Results for Yesintek Biosimilar in Psoriasis Treatment Biocon Biologics has announced successful Phase 3 trial results for Yesintek™, a biosimilar to Ustekinumab, promising new hope in psoriasis treatment.

Biocon Biologics Reports Promising Phase 3 Results for Yesintek Biosimilar in Psoriasis Treatment #India #Bengaluru #Biocon #YESINTEK #Psoriasis

Yesintek Gets FDA Approval as the Sixth Biosimilar to Stelara!

We are excited to share that YESINTEK™, a biosimilar to Stelara® (Ustekinumab), has been approved by the U.S. FDA!

📩 Contact us theindianpharma.com/blog-post/fd... today to learn more!
#FDAApproval #Yesintek #TheIndianPharma

PHARMA - 9 December 2024 🔊Biocon Biologics' Yesintek Receives Green Light From FDA YESINTEK™ is approved for use in Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a biosimilar option ...

Weekly Roundup - PHARMA - 9 December 2024

www.linkedin.com/pulse/pharma...

➡ kstrategyand.com/pharma-news

#BioconBiologics #Yesintek #BPZE1 #Roche #SanDiegoBiotech #PTC #Novartis #HuntingtonsDiseaseDrug #GSK #Pharma #Healthcare #ClinicalTrials #Humanteconomy #Humantec

FDA Greenlights Biocon Biologics' YESINTEK™, A Biosimilar Similar to Stelara® Biocon Biologics has received FDA approval for YESINTEK™, a biosimilar to J&J's Stelara®, expanding treatment options for Crohn's disease and more.

FDA Greenlights Biocon Biologics' YESINTEK™, A Biosimilar Similar to Stelara® #United_States #Biocon #YESINTEK #Stelara #Bridgewater,_New_Jersey